D'Souza DC

Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA.

9 papers · ORCID

ArticlePsilocybin

Comparing single- and repeat-dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial.

Schindler EAD, Gottschalk CH, Pittman BP +1

Europe PMC2026
ArticlePsychedelics

Addressing blinding in classic psychedelic studies with innovative active placebos.

Aday JS, Simonsson O, Schindler EAD +1

Europe PMC2025
ArticlePsilocybin

Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial.

Sloshower J, Zeifman RJ, Guss J +5

Europe PMC2024
ArticlePsilocybin

Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile.

Holze F, Singh N, Liechti ME +1

Europe PMC2024
ArticlePsilocybin

Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms.

Skosnik PD, Sloshower J, Safi-Aghdam H +4

Europe PMC2023
ArticlePsilocybin

Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial.

Sloshower J, Skosnik PD, Safi-Aghdam H +4

Europe PMC2023
ArticleDMT

Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder.

D'Souza DC, Syed SA, Flynn LT +3

Europe PMC2022
ArticlePsilocybin

Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin.

Schindler EAD, Sewell RA, Gottschalk CH +6

Europe PMC2021
ArticlePsychedelics

Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics.

Schindler EAD, Wallace RM, Sloshower JA +1

Europe PMC2018